Systemic therapy for metastatic prostate cancer has radically changed in the last 10 years with the introduction of several novel agents that have shown significant improvements in progression free and overall survival (see table 1 ). These have largely been studied in metastatic castrate-refractory prostate cancer (mCRPC) and have prolonged survival but in each case by less than 6 months . The treatment of these men has not significantly changed since Huggins and Hodges first demonstrated the effects of castration and androgen deprivation remains the mainstay of systemic treatment. However the latest breakthrough in the treatment of metastatic disease is the introduction of a relatively old drug, docetaxel chemotherapy, earlier in the disease for hormone sensitive patients. This article is protected by copyright. All rights reserved. 
